Home » Newsletters » BioWorld Science

BioWorld Science

July 30, 2012

View Archived Issues

Apogenix reports phase II APG-101 results

New orexin receptor antagonists patented by Actelion Pharmaceuticals

Phase II program on transdermal patch for schizophrenia begins

Study links ABC transporter gene polymorphisms to liver transplant outcomes

Pharmacodynamic efficacy of E-2096 described in animals and humans

Chinese researchers discover novel DPP IV inhibitors

Abbott presents new GSK-3 beta inhibitors

Sanofi reports novel Akt phosphorylation inhibitors

Spanish group synthesizes novel anti-inflammatory agents

Dainippon Sumitomo reviews events of first quarter fiscal 2012

StemCells receives California Institute for Regenerative Medicine award

GlaxoSmithKline develops novel orexin receptor antagonists

FDA advisory committee recommends ocriplasmin approval

Abbott and Enanta design new HCV NS3 protease inhibitors

Genentech reports on BREVACTA trial

SNPs affecting gene expression linked to late-onset Alzheimer's disease risk

NIH funds development of tissue chips to predict drug safety

Chugai Pharmaceutical profiles progress of second quarter 2012

Nuvo Research receives additional funding commitment for reformulated WF-10

Advinus Therapeutics and P2D Bioscience collaborate on ADHD

International collaboration yields new solution to defect regeneration in load-bearing long bones

Arena Pharmaceuticals transfers NDA rights to Eisai

Roche and Areva Med collaborate on radioimmunotherapy

Takeda resubmits alogliptin product NDAs

Basilea Pharmaceutica seeks European approval of antibiotic to treat pneumonia in hospitals

Shionogi seeks Japanese approval of combination drug for hypertension

Tokyo Institute of Technology and Astellas Pharma collaborate on neglected tropical diseases

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026